Anzeige
Meldung des Tages: Breaking News: Diese Goldaktie zündet den Turbo – Bohrstart bei Ceibal HEUTE verkündet!

Inventiva News

Aktie
WKN:  A2DLV9 ISIN:  FR0013233012 US-Symbol:  IVEVF Branche:  Biotechnologie Land:  Frankreich
5,25 €
+0,03 €
+0,57%
17:13:38 Uhr
Depot/Watchlist
Marktkapitalisierung *
328,73 Mio. €
Streubesitz
40,63%
KGV
-4,80
Index-Zuordnung
-

Inventiva News

26.02.26 - GlobeNewswire
Inventiva to Participate in Four Upcoming March Investor Conferences
Daix (France), New York (United States), February 26, 2026  – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical company ...
17.02.26 - GlobeNewswire
Inventiva reports preliminary 2025¹ fiscal year financial results
Cash and cash equivalents at €99.3 million, and €131.6 million in short-​term deposits 2 as of December 31, 2025 Revenues of €4.5 million in 2025 Completed a U.S. registered public ...
04.02.26 - GlobeNewswire
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Daix (France), New York (United States), February 4, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical company ...
26.01.26 - GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-​stage ...
17.12.25 - GlobeNewswire
Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference
Daix (France), New York City (New York, United States), December 17, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-​stage ...
28.11.25 - GlobeNewswire
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
Daix (France), New York City (New York, United States), November 28, 2025  – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-​stage biopharmaceutical company ...
24.11.25 - GlobeNewswire
Information relating to the stabilization activities carried out in the context of its recent offering
Daix (France), New York City (New York, United States), November 24, 202 5 – Publication of information relating to the stabilization activities carried out in the context of the recent ...
21.11.25 - GlobeNewswire
Inventiva reports 2025 Third Quarter Financial Information¹
Cash and cash equivalents at €97.6 million, and €24.7 million in short-​term deposits 2 as of September 30, 2025. Revenues of €4.5 million for the first nine months of 2025. Cash ...
17.11.25 - GlobeNewswire
Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5M
Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-​stage ...
13.11.25 - GlobeNewswire
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-​stage ...
12.11.25 - GlobeNewswire
Inventiva announces launch of public offering
Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-​stage ...
06.11.25 - GlobeNewswire
Combined General Meeting of November 27, 2025 - Availability of the preparatory documents
Daix (France), New York City (New York, United States), November 6,  2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-​stage ...
06.11.25 - GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as October 20, 2025
Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www . i n v e n t i v a p ha r m a. c om Date Number ...
14.10.25 - GlobeNewswire
Inventiva Announces the Implementation of a New ATM Program
Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-​stage ...
07.10.25 - GlobeNewswire
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 study Presentation of digital pathology data from preclinical ...
01.10.25 - GlobeNewswire
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
Daix (France), New York City (New York, United States), October 1, 2025  – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
29.09.25 - GlobeNewswire
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update  
Cash and cash equivalents at €146.7 million including €24.6 million in short-​term deposits 1 as of June 30, 2025 Receipt of the gross proceeds of €115.6 million from the second ...
24.09.25 - GlobeNewswire
Inventiva to Host Analyst and Investor Event on October 8, 2025
Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026 Three renowned ...
04.09.25 - GlobeNewswire
Inventiva to Participate in Upcoming September Investor Conferences
Daix (France), New York City (New York, United States), September 4, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-​stage ...
11.08.25 - GlobeNewswire
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Daix (France), New York City (New York, United States), August 11, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...

Newssuche

Videos

newspaper
16.03.26 +0,69%
Technical Trading: 82 Prozent Trefferquote
S&P 500 Long Typ: Open End Turbo WKN: VG93RW Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »